AIT-082 Phase 1B Study

National Institutes of Health (NIH)

Status and phase: Completed; Phase 1

Conditions: Memory Disorders

Treatments: Drug: AIT-082

Study type: Interventional

Funder types: NIH

Identifiers

NCT00000180

IA0008

3U01AG010483-08S2 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits.

This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria